The ICIs nivolumab and pembrolizumab, used in the treatment of metastatic melanoma, act by blocking the interaction of PD-1 with PD-L1/2, thereby inhibiting the PD-1 pathway and promoting immune system activation [7]. This evidence concerns the gene PDCD1 and metastatic melanoma.